Rilzabrutinib
CAS 1575591-66-0Small Molecule
Overview
Rilzabrutinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL3702854).
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Rilzabrutinib expires 20 Feb 2041 and exclusivity 29 Aug 2032. Generic API sourcing typically opens up once these lapse.
Chemical identity
- IUPAC name
- (E)-2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
- Canonical SMILES
- CC(C)(/C=C(\C#N)/C(=O)N1CCC[C@H](C1)N2C3=NC=NC(=C3C(=N2)C4=C(C=C(C=C4)OC5=CC=CC=C5)F)N)N6CCN(CC6)C7COC7
- InChIKey
- LCFFREMLXLZNHE-GBOLQPHISA-N
Verified Supplier Partner
Do you supply Rilzabrutinib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.